Search research articles
Contact Us
Filters
Showing results (101-110 of 268) with videos related to
Page
of 27
Sort By:
Frontiers in Oncology
|
October 21, 2024
Case report: dynamic personalized physiological monitoring in lung cancer using wearable data
Joshua W Bliss, Whitney P Underwood, Adele M Carlson, et al.
Immunotherapy
|
July 3, 2026
Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis
Nicolas Peruzzo, Gabriel Lenz, Rafael Alvim Pereira, et al.
Cancer Discovery
|
March 28, 2013
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas
Alexander Drilon, Lu Wang, Adnan Hasanovic, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo, Lynne D Berry, Dara L Aisner, et al.
Molecular Cancer Therapeutics
|
October 9, 2021
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Brion W Murray, Evan Rogers, Dayong Zhai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2015
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon, Lu Wang, Maria E Arcila, et al.
JTO Clinical and Research Reports
|
February 24, 2025
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
Rachel E Reingold, Rose Parisi, Guilherme Harada, et al.
Molecular Cancer Research : MCR
|
February 12, 2022
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer
Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, et al.
The Lancet. Oncology
|
September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Vivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Oliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
Page
of 27
Search research articles
Search
Showing results (101-110 of 268) with videos related to
Sort By:
Page
of 27
Frontiers in Oncology
|
October 21, 2024
Case report: dynamic personalized physiological monitoring in lung cancer using wearable data
Joshua W Bliss, Whitney P Underwood, Adele M Carlson, et al.
Immunotherapy
|
July 3, 2026
Anti-PD-(L)1 plus chemotherapy in advanced PD-L1-negative nonsquamous non-small cell lung cancer: a systematic review and meta-analysis
Nicolas Peruzzo, Gabriel Lenz, Rafael Alvim Pereira, et al.
Cancer Discovery
|
March 28, 2013
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas
Alexander Drilon, Lu Wang, Adnan Hasanovic, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2019
MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium
Robin Guo, Lynne D Berry, Dara L Aisner, et al.
Molecular Cancer Therapeutics
|
October 9, 2021
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Brion W Murray, Evan Rogers, Dayong Zhai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 9, 2015
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches
Alexander Drilon, Lu Wang, Maria E Arcila, et al.
JTO Clinical and Research Reports
|
February 24, 2025
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
Rachel E Reingold, Rose Parisi, Guilherme Harada, et al.
Molecular Cancer Research : MCR
|
February 12, 2022
MYC Promotes Tyrosine Kinase Inhibitor Resistance in ROS1-Fusion-Positive Lung Cancer
Sudarshan R Iyer, Igor Odintsov, Adam J Schoenfeld, et al.
The Lancet. Oncology
|
September 15, 2022
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
Vivek Subbiah, Jürgen Wolf, Bhavana Konda, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Oliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
Page
of 27